Regeneron Pharmaceuticals received FDA approval for Lynozyfic, a bispecific antibody for multiple myeloma treatment, distinguished by enhanced dosing flexibility over competitors from Johnson & Johnson and Pfizer. This approval expands therapeutic options within the bispecific antibody class, offering clinicians refined control in managing multiple myeloma patients.